GNF SymAtlas + NCI-60 cancer cell lines, comparison of cancers vs non-cancers, human (Su, 2004; Ross, 2000)
Gene Symbol | Gene ID | Gene Info |
---|---|---|
ENSG00000006468.9 | ETS variant transcription factor 1 | |
ENSG00000105722.5 | ETS2 repressor factor | |
ENSG00000163497.2 | FEV transcription factor, ETS family member | |
ENSG00000120690.9 | E74 like ETS transcription factor 1 |
Gene | Promoter | Pearson corr. coef. | P-value | Plot |
---|---|---|---|---|
ELF1 | hg19_v2_chr13_-_41593425_41593480 | -0.72 | 1.3e-35 | Click! |
ERF | hg19_v2_chr19_-_42759300_42759324 | 0.28 | 3.2e-05 | Click! |
ETV1 | hg19_v2_chr7_-_14026063_14026091 | -0.13 | 6.4e-02 | Click! |
FEV | hg19_v2_chr2_-_219850277_219850379 | -0.01 | 8.4e-01 | Click! |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
4.1 | 300.3 | GO:0070125 | mitochondrial translational elongation(GO:0070125) mitochondrial translational termination(GO:0070126) |
5.2 | 250.9 | GO:0006370 | 7-methylguanosine mRNA capping(GO:0006370) |
2.5 | 231.7 | GO:0051436 | negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle(GO:0051436) regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle(GO:0051439) |
1.7 | 227.1 | GO:0006626 | protein targeting to mitochondrion(GO:0006626) |
2.3 | 175.6 | GO:0048208 | vesicle targeting, rough ER to cis-Golgi(GO:0048207) COPII vesicle coating(GO:0048208) |
20.9 | 167.0 | GO:0003065 | positive regulation of heart rate by epinephrine(GO:0003065) |
6.4 | 159.6 | GO:0045899 | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly(GO:0045899) |
4.4 | 144.7 | GO:0006221 | pyrimidine nucleotide biosynthetic process(GO:0006221) |
4.7 | 137.4 | GO:0051131 | chaperone-mediated protein complex assembly(GO:0051131) |
41.6 | 124.7 | GO:0006427 | histidyl-tRNA aminoacylation(GO:0006427) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.4 | 275.2 | GO:0005739 | mitochondrion(GO:0005739) |
0.9 | 262.9 | GO:0005743 | mitochondrial inner membrane(GO:0005743) |
0.5 | 255.4 | GO:0044429 | mitochondrial part(GO:0044429) |
12.5 | 225.9 | GO:0034709 | methylosome(GO:0034709) |
4.8 | 193.3 | GO:0005762 | organellar large ribosomal subunit(GO:0000315) mitochondrial large ribosomal subunit(GO:0005762) |
16.0 | 191.9 | GO:0031595 | nuclear proteasome complex(GO:0031595) |
5.8 | 174.4 | GO:0030687 | preribosome, large subunit precursor(GO:0030687) |
10.0 | 169.2 | GO:0032059 | bleb(GO:0032059) |
0.8 | 168.2 | GO:0001726 | ruffle(GO:0001726) |
2.6 | 135.5 | GO:0008180 | COP9 signalosome(GO:0008180) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.8 | 262.3 | GO:0005525 | GTP binding(GO:0005525) |
2.4 | 236.7 | GO:0008307 | structural constituent of muscle(GO:0008307) |
4.4 | 232.9 | GO:0005154 | epidermal growth factor receptor binding(GO:0005154) |
3.2 | 171.2 | GO:0050136 | NADH dehydrogenase (ubiquinone) activity(GO:0008137) NADH dehydrogenase (quinone) activity(GO:0050136) |
14.6 | 160.3 | GO:0036402 | proteasome-activating ATPase activity(GO:0036402) |
1.5 | 126.9 | GO:0051082 | unfolded protein binding(GO:0051082) |
41.6 | 124.7 | GO:0004821 | histidine-tRNA ligase activity(GO:0004821) |
5.4 | 124.4 | GO:0008353 | RNA polymerase II carboxy-terminal domain kinase activity(GO:0008353) |
3.4 | 124.1 | GO:0000175 | 3'-5'-exoribonuclease activity(GO:0000175) |
1.6 | 116.0 | GO:0019003 | GDP binding(GO:0019003) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
3.0 | 168.3 | PID AURORA A PATHWAY | Aurora A signaling |
5.4 | 141.7 | PID ARF 3PATHWAY | Arf1 pathway |
3.1 | 130.5 | PID EPHA FWDPATHWAY | EPHA forward signaling |
8.2 | 114.6 | SA G2 AND M PHASES | Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition. |
2.1 | 114.6 | PID FOXM1 PATHWAY | FOXM1 transcription factor network |
2.8 | 95.9 | PID SYNDECAN 3 PATHWAY | Syndecan-3-mediated signaling events |
2.2 | 93.6 | PID SYNDECAN 2 PATHWAY | Syndecan-2-mediated signaling events |
2.5 | 92.1 | PID HIF1A PATHWAY | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha |
3.0 | 84.9 | PID DNA PK PATHWAY | DNA-PK pathway in nonhomologous end joining |
2.8 | 73.4 | SA G1 AND S PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
5.7 | 465.0 | REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G | Genes involved in Vif-mediated degradation of APOBEC3G |
4.9 | 301.2 | REACTOME MITOCHONDRIAL PROTEIN IMPORT | Genes involved in Mitochondrial Protein Import |
3.4 | 271.0 | REACTOME RESPIRATORY ELECTRON TRANSPORT | Genes involved in Respiratory electron transport |
4.2 | 267.4 | REACTOME SMOOTH MUSCLE CONTRACTION | Genes involved in Smooth Muscle Contraction |
7.0 | 204.1 | REACTOME FORMATION OF INCISION COMPLEX IN GG NER | Genes involved in Formation of incision complex in GG-NER |
1.1 | 176.2 | REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION | Genes involved in Antigen processing: Ubiquitination & Proteasome degradation |
2.9 | 154.2 | REACTOME TRNA AMINOACYLATION | Genes involved in tRNA Aminoacylation |
1.7 | 152.3 | REACTOME MHC CLASS II ANTIGEN PRESENTATION | Genes involved in MHC class II antigen presentation |
5.7 | 125.8 | REACTOME RETROGRADE NEUROTROPHIN SIGNALLING | Genes involved in Retrograde neurotrophin signalling |
6.6 | 125.3 | REACTOME PECAM1 INTERACTIONS | Genes involved in PECAM1 interactions |